Literature DB >> 34587877

Paediatric Active Enhanced Disease Surveillance (PAEDS) 2019: Prospective hospital-based surveillance for serious paediatric conditions.

Nicole Dinsmore1, Jocelynne E McRae1,2, Helen E Quinn3,4, Catherine Glover5, Sonia Dougherty6, Alissa McMinn7, Nigel Crawford8, Helen Marshall9, Samantha J Carlson10, Christopher Blyth11,12, Ryan Lucas2,13, Adam Irwin14, Kristine Macartney4,5,15,16, Nicholas Wood4,17,18.   

Abstract

INTRODUCTION: The Paediatric Active Enhanced Disease Surveillance (PAEDS) network is an Australian hospital-based active surveillance system employing prospective case ascertainment for selected serious childhood conditions, particularly vaccine preventable diseases and potential adverse events following immunisation (AEFI). This report presents surveillance data for 2019.
METHODS: Specialist nurses screened hospital admissions, emergency department records, laboratory and other data on a daily basis in seven paediatric tertiary referral hospitals across Australia, to identify children with the conditions under surveillance. Standardised protocols and case definitions were used across all sites. In 2019, the conditions under surveillance comprised: acute flaccid paralysis (AFP; a syndrome associated with poliovirus infection), acute childhood encephalitis (ACE), influenza, intussusception (IS; a potential AEFI with rotavirus vaccines), pertussis, varicella-zoster virus infection (varicella and herpes zoster), invasive meningococcal and invasive Group A streptococcus diseases and two new conditions, Kawasaki disease and gram-negative bloodstream infections. An additional social research component continued to evaluate parental attitudes to influenza vaccination.
RESULTS: PAEDS captured 2,701 cases for 2019 across all conditions under surveillance. Key outcomes of PAEDS included: contribution to national AFP surveillance to reach the World Health Organization reporting targets for detection of poliomyelitis cases; demonstration of high influenza activity in 2019 and influenza-associated deaths in ACE cases; identification of key barriers to influenza vaccination of children hospitalised for acute respiratory illness; reporting of all IS cases associated with vaccine receipt to relevant state health department; and showing a further reduction nationally in varicella cases. Enhanced pertussis surveillance continued to capture controls to support vaccine efficacy estimation. Invasive meningococcal disease surveillance showed predominance of serotype B and a reduction in cases nationally. Surveillance for invasive group A streptococcus captured severe cases in children. Monitoring of Kawasaki disease incidence and gram-negative bloodstream infections commenced.
CONCLUSIONS: PAEDS continues to provide unique policy-relevant data on serious paediatric conditions using sentinel hospital-based enhanced surveillance. Keywords: paediatric, surveillance, child, hospital, vaccine preventable diseases, adverse event following immunisation, acute flaccid paralysis, encephalitis, influenza, intussusception, pertussis, varicella zoster virus, meningococcal, group A streptococcus, Kawasaki, bloodstream infections. © Commonwealth of Australia CC BY-NC-ND.

Entities:  

Keywords:  Kawasaki; acute flaccid paralysis; adverse event following immunisation; bloodstream infections; child; encephalitis; group A streptococcus; hospital; influenza; intussusception; meningococcal; pertussis; surveillance; vaccine preventable diseases; varicella zoster virus; paediatric

Mesh:

Substances:

Year:  2021        PMID: 34587877     DOI: 10.33321/cdi.2021.45.53

Source DB:  PubMed          Journal:  Commun Dis Intell (2018)        ISSN: 2209-6051


  1 in total

1.  Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant.

Authors:  Laura Lopez; David Burgner; Catherine Glover; Jeremy Carr; Julia Clark; Alison Boast; Nan Vasilunas; Brendan McMullan; Joshua R Francis; Asha C Bowen; Christopher C Blyth; Kristine Macartney; Nigel W Crawford; Emma Carey; Nicholas Wood; Philip N Britton
Journal:  Lancet Reg Health West Pac       Date:  2022-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.